What Amber Plasma A.S. does

Amber Plasma A.S. is a private Czech joint-stock company headquartered in Prague that operates a network of 12 blood plasma donation centers across the Czech Republic, with concentration in western and northern Bohemia (Prague-Nové Butovice, Plzeň, Teplice, Karlovy Vary, Chomutov, Děčín, Jablonec nad Nisou, Mladá Boleslav, Česká Lípa, Příbram, Cheb, and Litoměřice). The company performs plasmapheresis using automated blood component separation equipment, returning red blood cells to the donor and retaining plasma that is shipped for fractionation into pharmaceutical products (albumin, immunoglobulins, clotting factors, alpha-1 antitrypsin). It is a member of the French biopharmaceutical group LFB (Laboratoire Français du Fractionnement et des Biotechnologies) and the Europlasma Group, providing it with an integrated offtake into one of the world's leading plasma fractionators.

The business model is built around compensated plasma collection under Czech law (Section 32, Act 373/2011), paying donors 900 Kč per successful donation, with eligible donations every 14 days (maximum 26 per year). Donors may alternatively opt for a tax deduction of up to 3,000 Kč per donation (capped at 15% of annual taxable income). Customer acquisition runs direct-to-consumer through the company's website, the Moje Amber donor portal (darce.amberplasma.com), a free phone hotline (800 606 806), a 1,000 Kč referral bonus program, and the Amber Club/Amber Coiny loyalty scheme. The primary customer segment is healthy adults aged 18-65 weighing over 50 kg with EU health insurance; the underlying end beneficiaries are European patients dependent on plasma-derived therapies (approximately 300,000 per PPTA data).

The operational platform combines physical donor centers, a web-based reservation and rewards portal, an internal whistleblowing system (Trust Box/Schránka důvěry) operated by Gappex s.r.o. under Czech Whistleblowing Act No. 171/2023 Coll., and a data protection framework compliant with GDPR. The company employs 251-500 staff and was founded in 2007. Strategic positioning centers on geographic convenience, donor retention via loyalty and recurring health check-ups, and vertical integration through LFB Group affiliation, rather than technology differentiation.

Name

Amber Plasma A.S.

Legal name

Amber Plasma a.s.

Website

https://amberplasma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

Amber Plasma A.S. operates 12 blood plasma donation centers across the Czech Republic, paying donors 900 Kč per collection under Czech law. It is part of French biopharmaceutical group LFB, supplying plasma for fractionation into life-saving therapies for European patients.

Ownership category

akta.pro rank

Product category

Plasma Collection Services

NAICS

Blood and Organ Banks (621991)

akta.pro primary industry

Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)

Keywords

• Plasma donation services
• Plasmapheresis collection
• Blood plasma centers
• Plasma-derived medicines
• Donor compensation

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices12 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Plasma Donation Services: Amber Plasma operates plasma collection centers where donors receive financial compensation (900 Kč per donation, capped by law at 5% of minimum wage per Section 32 of Act 373/2011). The collected plasma is processed into pharmaceutical products including albumin, immunoglobulins, clotting factors, and other plasma proteins. The company is part of LFB Group, a French biopharmaceutical company that processes plasma into life-saving medicines.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Amber Plasma A.S. operates a network of 12 plasma donation centers across the Czech Republic, collecting human blood plasma from voluntary donors through plasmapheresis. Donors receive 900 Kč financial compensation per donation (capped by law) and can donate every 14 days. The collected plasma is supplied to its parent group LFB, a French biopharmaceutical company that fractionates the plasma into life-saving medicines such as albumin, immunoglobulins, and clotting factors.

Product overview

Amber Plasma A.S. operates a network of 12 blood plasma donation centers across the Czech Republic, offering plasmapheresis donation services. The company is part of the French biopharmaceutical group LFB. The core offering is blood plasma collection, supported by the Moje Amber donor portal for reservations and profile management, the Amber Club loyalty program for rewards redemption, and a whistleblowing system (Trust Box) for employee reporting. Donors receive 900 Kč financial compensation per donation, with plasma used for manufacturing life-saving medications for patients with hemophilia, immune disorders, and other conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Blood Plasma Donation Services

Quantifiable outcome

• Plasma regenerates in 48 hours, allowing donations every 14 days
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core and minor.

• LFB (Laboratoire Français du Fractionnement et des Biotechnologies)coreStrategic or Co-development PartnerLFB is a French biopharmaceutical company and one of the world leaders in plasma processing. Amber Plasma is part of the LFB Group, which processes collected plasma into life-saving pharmaceutical products including albumin, immunoglobulins, and clotting factors.
• Europlasma GroupcoreStrategic or Co-development PartnerInternational parent group of which Amber Plasma is a member, providing international backing and access to global best practices in plasma collection and processing.
• Gappex s.r.o.minorImplementation/ SI/ Consulting PartnerExternal ombudsman provider for whistleblower system (Whistleblowing/Sránka důvěry). Operates the SmartFP application for anonymous reporting of concerns. Contact: Jana Burianová, +420 725 560 624.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• BioLife Plasma Services: Takeda-owned plasma collection network with hundreds of centers, primarily in the US and growing in Europe. Mirrors Amber Plasma's transactional donor-compensation model, multi-center footprint, and downstream linkage to a major plasma fractionator.
• CSL Plasma: The world's largest plasma collection network, operated as the collection arm of CSL Behring. Directly comparable to Amber Plasma in core service (paid plasmapheresis), customer (compensated adult donors), and value chain position (collector feeding a fractionator parent).
• ADMA Biologics: US end-to-end plasma company combining collection centers with fractionation focused on immune globulins. Comparable as a smaller-scale vertically integrated plasma collector/fractionator competing in the same downstream immunoglobulin markets.
• Octapharma Plasma: US- and Europe-based paid plasma collection arm of Octapharma AG. Operates the same donor-centre/automated-plasmapheresis model as Amber Plasma and feeds parent fractionation capacity for immunoglobulins and coagulation products.

Regional players

• Sanquin Plasma Products: Dutch blood bank's plasma division operating collection programs in the Netherlands. Comparable as a European regional collector-fragmentation operator serving a single national market, similar to Amber Plasma's Czech Republic footprint.
• Haema AG: German blood and plasma donation service operating donor centers across Germany. Comparable as a regional (DACH) plasma collector serving a single national market with a similar centre-network and compensated-donor model.

Broad incumbents

• Bio Products Laboratory (BPL): UK-based plasma fractionator supplying albumin and immunoglobulins globally, with associated plasma collection programs. Comparable as a European incumbent sitting downstream of Amber Plasma's collection activity.
• Grifols: Global plasma-derived therapy leader operating its own plasma collection network plus fractionation, purification, fill-finish, and diagnostics. Comparable as a broader incumbent in the same plasma value chain that Amber Plasma supplies into.
• Kedrion: Italian biopharmaceutical company fractionating plasma into therapeutic products, with affiliated collection programs in multiple countries. Comparable as a vertically integrated incumbent in the European plasma value chain.
• Biotest AG: German plasma products specialist (immunoglobulins, coagulation factors, albumin) with associated plasma collection operations. Comparable as a European incumbent combining plasma sourcing and fractionation in the same downstream categories Amber Plasma ultimately supplies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/amber-plasma-a-s

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amber Plasma A.S.